Alexza Pharmaceuticals has announced the appointment of Michael S. Holfinger as Vice President, Manufacturing & Global Supply Chain Management. Holfinger was most recently Vice President, Manufacturing & CMC Development at Affymax. Alexza recently announced that Teva will market the company's Adasuve inhaled loxapine in the US. Holfinger commented, "With the … [Read more...] about Alexza hires Michael Holfinger as VP, Manufacturing & Global Supply Chain Management
News
Kamada gets new patents for inhaled AAT
Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and the Australian Patent, No. 2007213344, is titled “Pulmonary … [Read more...] about Kamada gets new patents for inhaled AAT
Coster announces US DMF number for MDI valves
Italian aerosol device and filling machine company Coster Pharma has announced that its Type 3 Drug Master File (DMF) for two of its MDI valves to the FDA has been issued the DMF number 26960. Both of the 20mm valves are manufactured at the company's clean room facility in Trento, Italy. The 20DR valve is available for 50, 65, 75, and 100 µl dosing, and the 20DPH … [Read more...] about Coster announces US DMF number for MDI valves
Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation
Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson's disease patients, the company said. The grant will support a Phase 2b trial of the carrier-free dry powder formulation. The foundation previously awarded … [Read more...] about Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation
MicroDose Therapeutx acquired by Teva
Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and royalties. Calling the acquisition "a significant step toward expanding its respiratory pipeline," the company cited MicroDose’s proprietary dry … [Read more...] about MicroDose Therapeutx acquired by Teva
Elan shareholders reject Theravance deal
Shareholders of Elan Corporation have rejected the company's $1 billion deal for royalties from Theravance inhaled drugs, including the Breo and Anoro Ellipta DPIs. Anticipating the result from the Theravance vote, Elan announced on June 14 that it would put itself up for sale. Theravance CEO Rick Winningham responded to the vote saying, "While we are disappointed … [Read more...] about Elan shareholders reject Theravance deal
Theravance deal in doubt, Elan board goes forward with sale process
So many shareholders have already voted against Elan's proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan shareholders on June 17. Without citing any reason, Elan's board has now announced that it will proceed with the sale of the company, saying that … [Read more...] about Theravance deal in doubt, Elan board goes forward with sale process
Aptar Pharma provides multi-lingual site for international customers
OINDP device maker Aptar Pharma has added Chinese, French, German and Spanish versions to its English-language website and plans to add additional languages, including Portuguese, in 2014. According to the company, web traffic has grown more than 100% since the Aptar Pharma site was launched in 2011. Visitors to the site can locate devices organized by application, … [Read more...] about Aptar Pharma provides multi-lingual site for international customers
Pearl Therapeutics to be acquired by AstraZeneca
AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if sales goals are met. Pearl announced the initiation of a Phase 3 program for its PT003 formoterol fumarate/glycopyrrolate MDI for the treatment of COPD in … [Read more...] about Pearl Therapeutics to be acquired by AstraZeneca
Justin Hughey to head Hovione’s US particle design team
Hovione has announced the appointment of Justin Hughey, who was most recently Director of Research for Enavail to head its US Particle Design sciences at our site in New Jersey. The company says that it is moving into hot melt extrusion in addition to spray drying, and Hughey has extensive experience with the technique. He also has experience in engineering particles … [Read more...] about Justin Hughey to head Hovione’s US particle design team